{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:54:03Z","timestamp":1791330843603,"version":"4.3.1"},"reference-count":91,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["848043004"],"award-info":[{"award-number":["848043004"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016304","name":"Medtronic","doi-asserted-by":"publisher","award":["A1395092\/SH-3950"],"award-info":[{"award-number":["A1395092\/SH-3950"]}],"id":[{"id":"10.13039\/100016304","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016304","name":"Medtronic","doi-asserted-by":"publisher","award":["NCT04061798"],"award-info":[{"award-number":["NCT04061798"]}],"id":[{"id":"10.13039\/100016304","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jtha.2026.03.017","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:46:03Z","timestamp":1774658763000},"page":"2025-2039","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical applicability of anti-Xa measurements to monitor unfractionated heparin activity during arterial procedures: a scoping review"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5059-0107","authenticated-orcid":false,"given":"Max","family":"Hoebink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.H.","family":"Steunenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sjoerd","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrike M.","family":"Hamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arno M.","family":"Wiersema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kak Khee","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Jongkind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2026.03.017_bib1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejvsvf.2025.01.005","article-title":"Strategies for antithrombotic management during non-cardiac arterial procedures: results of the international ACTION survey","volume":"64","author":"Hoebink","year":"2025","journal-title":"EJVES Vasc Forum"},{"key":"10.1016\/j.jtha.2026.03.017_bib2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jtha.2022.11.014","volume":"21","author":"Helms","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.03.017_bib3","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.bja.2025.01.015","article-title":"2024 EACTS\/EACTAIC\/EBCP guidelines on cardiopulmonary bypass in adult cardiac surgery","volume":"134","author":"Wahba","year":"2025","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.jtha.2026.03.017_bib4","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/00003088-199222050-00003","article-title":"Heparin pharmacokinetics and pharmacodynamics","volume":"22","author":"Kandrotas","year":"1992","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jtha.2026.03.017_bib5","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.jtcvs.2012.05.065","article-title":"Subtle differences in commercial heparins can have serious consequences for cardiopulmonary bypass patients: a randomized controlled trial","volume":"144","author":"Arsenault","year":"2012","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtha.2026.03.017_bib6","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ejvs.2025.07.027","article-title":"Editor\u2019s choice\u2014Activated Clotting Time Guided Heparinisation during Open Abdominal Aortic Aneurysm Repair (ACTION-1): a randomised, multicentre, single blind, superiority trial","volume":"70","author":"Jongkind","year":"2025","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.jtha.2026.03.017_bib7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archinte.1994.00420010073009","article-title":"A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin","volume":"154","author":"Levine","year":"1994","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jtha.2026.03.017_bib8","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/j.1875-9114.2011.01049.x","article-title":"Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin","volume":"32","author":"Vandiver","year":"2012","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jtha.2026.03.017_bib9","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/0049-3848(76)90034-7","article-title":"Assay of heparin in plasma using a chromogenic substrate for activated factor X","volume":"8","author":"Teien","year":"1976","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.03.017_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/17474086.2023.2169126","article-title":"Application of anti-Xa assay in monitoring unfractionated heparin therapy in contemporary antithrombotic management","volume":"16","author":"Safani","year":"2023","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.jtha.2026.03.017_bib11","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1182\/blood.V49.2.171.171","article-title":"Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis","volume":"49","author":"Chiu","year":"1977","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.03.017_bib12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1051\/ject\/201244015","article-title":"Comparison of point-of-care activated clotting time systems utilized in a single pediatric institution","volume":"44","author":"Ojito","year":"2012","journal-title":"J Extra Corpor Technol"},{"key":"10.1016\/j.jtha.2026.03.017_bib13","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1053\/j.jvca.2020.06.027","article-title":"Evaluation of point-of-care ACT coagulometers and anti-Xa activity during cardiopulmonary bypass","volume":"34","author":"Falter","year":"2020","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.jtha.2026.03.017_bib14","first-page":"488","article-title":"Unfractionated heparin and the activated clotting time in non-cardiac arterial procedures","volume":"64","author":"Roosendaal","year":"2023","journal-title":"J Cardiovasc Surg (Torino)"},{"key":"10.1016\/j.jtha.2026.03.017_bib15","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1213\/00000539-199011000-00017","article-title":"Baseline activated coagulation time should be measured after surgical incision","volume":"71","author":"Gravlee","year":"1990","journal-title":"Anesth Analg"},{"key":"10.1016\/j.jtha.2026.03.017_bib16","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1136\/emj.2005.032334","article-title":"The effects of commonly used resuscitation fluids on whole blood coagulation","volume":"23","author":"Coats","year":"2006","journal-title":"Emerg Med J"},{"key":"10.1016\/j.jtha.2026.03.017_bib17","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/ejh.13394","article-title":"Unexpected, isolated activated partial thromboplastin time prolongation: a practical mini-review","volume":"104","author":"Rasmussen","year":"2020","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtha.2026.03.017_bib18","first-page":"253","article-title":"Activated partial thromboplastin time monitoring of unfractionated heparin therapy: issues and recommendations","volume":"43","author":"Marlar","year":"2017","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2026.03.017_bib19","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1213\/ANE.0b013e31827e4e62","article-title":"Review article: heparin sensitivity and resistance: management during cardiopulmonary bypass","volume":"116","author":"Finley","year":"2013","journal-title":"Anesth Analg"},{"key":"10.1016\/j.jtha.2026.03.017_bib20","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jvs.2017.11.079","article-title":"Comparison between activated clotting time and anti-activated factor X activity for the monitoring of unfractionated heparin therapy in patients with aortic aneurysm undergoing an endovascular procedure","volume":"68","author":"Dieplinger","year":"2018","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.jtha.2026.03.017_bib21","doi-asserted-by":"crossref","first-page":"4281","DOI":"10.1053\/j.jvca.2022.07.030","article-title":"A pilot study to assess the clinical onset of IV heparin in interventional cardiology and cardiac surgery","volume":"36","author":"Asher","year":"2022","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.jtha.2026.03.017_bib22","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2026.03.017_bib23","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1213\/01.ANE.0000096260.35340.C5","article-title":"Heparin-level-based anticoagulation management during cardiopulmonary bypass: a pilot investigation on the effects of a half-dose aprotinin protocol on postoperative blood loss and hemostatic activation and inflammatory response","volume":"98","author":"Koster","year":"2004","journal-title":"Anesth Analg"},{"key":"10.1016\/j.jtha.2026.03.017_bib24","doi-asserted-by":"crossref","first-page":"E599","DOI":"10.1532\/HSF98.20041134","article-title":"In vivo and in vitro evaluation of the heparin management test versus the activated coagulation time for monitoring anticoagulation level in aprotinin-treated patients during cardiac surgery","volume":"7","author":"Kim","year":"2004","journal-title":"Heart Surg Forum"},{"issue":"4 Pt 1","key":"10.1016\/j.jtha.2026.03.017_bib25","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0022-5223(05)80163-1","article-title":"Recombinant aprotinin in coronary artery bypass graft operations","volume":"110","author":"Green","year":"1995","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtha.2026.03.017_bib26","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1053-0770(99)90174-X","article-title":"Heparin management test versus activated coagulation time during cardiovascular surgery: correlation with anti-Xa activity","volume":"13","author":"Fitch","year":"1999","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.jtha.2026.03.017_bib27","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.3390\/diagnostics13081489","article-title":"Laboratory assessment of unfractionated heparin (UFH) with activated clotting time (ACT) and anti-Xa activity during peripheral arterial angiographic procedure","volume":"13","author":"Helin","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.jtha.2026.03.017_bib28","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1067\/mva.1991.29897","article-title":"Pharmacokinetics of low-molecular-weight heparin and unfractionated heparin during elective aortobifemoral bypass grafting","volume":"14","author":"Kroneman","year":"1991","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.jtha.2026.03.017_bib29","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S0950-821X(05)80593-6","article-title":"Time-related anticoagulation after regional and systemic administration of heparin in patients undergoing aortoiliac surgery","volume":"8","author":"Lindblad","year":"1994","journal-title":"Eur J Vasc Surg"},{"key":"10.1016\/j.jtha.2026.03.017_bib30","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0950-821X(89)80006-4","article-title":"The effect of a bolus injection of unfractionated or low molecular weight heparin during aortobifemoral bypass grafting","volume":"3","author":"Melissari","year":"1989","journal-title":"Eur J Vasc Surg"},{"key":"10.1016\/j.jtha.2026.03.017_bib31","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S1053-0770(97)90247-0","article-title":"Heparin detection by the activated coagulation time: a comparison of the sensitivity of coagulation tests and heparin assays","volume":"11","author":"Murray","year":"1997","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.jtha.2026.03.017_bib32","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0950-821X(87)80033-6","article-title":"Monitoring heparin and haemostasis during reconstruction of the abdominal aorta","volume":"1","author":"Porte","year":"1987","journal-title":"Eur J Vasc Surg"},{"key":"10.1016\/j.jtha.2026.03.017_bib33","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S1078-5884(96)80135-3","article-title":"Low molecular mass heparin instead of unfractionated heparin during infrainguinal bypass surgery","volume":"11","author":"Swedenborg","year":"1996","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.jtha.2026.03.017_bib34","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/bja\/ael194","article-title":"Anticoagulation monitoring during vascular surgery: accuracy of the Hemochron low range activated clotting time (ACT-LR)","volume":"97","author":"Tremey","year":"2006","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.jtha.2026.03.017_bib35","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/03009739209179282","article-title":"Heparin-coated cardiopulmonary bypass circuits and 25% reduction of heparin dose in coronary artery surgery\u2014a clinical study","volume":"97","author":"Borowiec","year":"1992","journal-title":"Upsala J Med Sci"},{"key":"10.1016\/j.jtha.2026.03.017_bib36","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1053\/j.jvca.2012.03.011","article-title":"An evaluation of factors affecting activated coagulation time","volume":"26","author":"Bosch","year":"2012","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.jtha.2026.03.017_bib37","first-page":"182","article-title":"Heparin or enoxaparin anticoagulation for primary percutaneous coronary intervention","volume":"77","author":"Brieger","year":"2011","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.jtha.2026.03.017_bib38","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1067\/mtc.2003.103","article-title":"Heparin versus danaparoid in off-pump coronary bypass grafting: Results of a prospective randomized clinical trial","volume":"125","author":"Carrier","year":"2003","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtha.2026.03.017_bib39","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1160\/TH08-08-0528","article-title":"Comparison of activated clotting times obtained using Hemochron and Medtronic analysers in patients receiving anti-thrombin therapy during cardiac catheterisation","volume":"101","author":"Chia","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.03.017_bib40","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1053\/j.jvca.2023.02.015","article-title":"Point-of-care viscoelastic hemostatic assays in cardiac surgery patients: comparison of thromboelastography 6S, thromboelastometry sigma, and quantra","volume":"37","author":"Demailly","year":"2023","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.jtha.2026.03.017_bib41","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/00001721-199710000-00007","article-title":"A comparison between continuous infusion versus standard bolus administration of heparin based on monitoring in cardiac surgery","volume":"8","author":"Despotis","year":"1997","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jtha.2026.03.017_bib42","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S0022-5223(94)70150-4","article-title":"Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations","volume":"108","author":"Despotis","year":"1994","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtha.2026.03.017_bib43","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1053\/j.jvca.2012.10.020","article-title":"Monitoring incomplete heparin reversal and heparin rebound after cardiac surgery","volume":"27","author":"Galeone","year":"2013","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.jtha.2026.03.017_bib44","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0022-5223(96)70191-5","article-title":"Measurement of heparin concentration in whole blood with the Hepcon\/HMS device does not agree with laboratory determination of plasma heparin concentration using a chromogenic substrate for activated factor X","volume":"112","author":"Hardy","year":"1996","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtha.2026.03.017_bib45","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1177\/0267659117692661","article-title":"Changes in heparin dose response slope during cardiac surgery: possible result in inaccuracy in predicting heparin bolus dose requirement to achieve target ACT","volume":"32","author":"Ichikawa","year":"2017","journal-title":"Perfusion"},{"key":"10.1016\/j.jtha.2026.03.017_bib46","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/00000539-200207000-00004","article-title":"The plasma supplemented modified activated clotting time for monitoring of heparinization during cardiopulmonary bypass: a pilot investigation","volume":"95","author":"Koster","year":"2002","journal-title":"Anesth Analg"},{"key":"10.1016\/j.jtha.2026.03.017_bib47","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/00000542-200210000-00014","article-title":"Hemostatic activation and inflammatory response during cardiopulmonary bypass: impact of heparin management","volume":"97","author":"Koster","year":"2002","journal-title":"Anesthesiology"},{"key":"10.1016\/j.jtha.2026.03.017_bib48","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1055\/s-0043-1770096","article-title":"Factors influencing anti-Xa assays: a multicenter prospective study in critically ill and noncritically ill patients receiving unfractionated heparin","volume":"123","author":"Lasne","year":"2023","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.03.017_bib49","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1053\/j.jvca.2019.12.050","article-title":"Heparin dose and point-of-care measurements of hemostasis in cardiac surgery-results of a randomized controlled trial","volume":"34","author":"Lax","year":"2020","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.jtha.2026.03.017_bib50","first-page":"578","article-title":"An investigation of a new activated clotting time \u201cMAX-ACT\u201d in patients undergoing extracorporeal circulation","volume":"92","author":"Leyvi","year":"2001","journal-title":"Anesth Analg"},{"key":"10.1016\/j.jtha.2026.03.017_bib51","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.amjcard.2005.01.071","article-title":"Comparison of enoxaparin versus heparin during elective percutaneous coronary intervention performed with either eptifibatide or tirofiban (the ACTION trial)","volume":"95","author":"Madan","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jtha.2026.03.017_bib52","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1053\/j.jvca.2018.01.027","article-title":"Assessment of heparin anticoagulation measured using i-STAT and hemochron activated clotting time","volume":"32","author":"Maslow","year":"2018","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.jtha.2026.03.017_bib53","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.thromres.2003.09.014","article-title":"Dextran sulfate included in factor Xa assay reagent overestimates heparin activity in patients after heparin reversal by protamine","volume":"111","author":"Mouton","year":"2003","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.03.017_bib54","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ahj.2005.06.020","article-title":"A randomized pilot study of dalteparin versus unfractionated heparin during percutaneous coronary interventions","volume":"151","author":"Natarajan","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.jtha.2026.03.017_bib55","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1051\/ject\/1995274197","article-title":"Correlation of ACT as measured with three commercially available devices with circulating heparin level during cardiac surgery","volume":"27","author":"Niles","year":"1995","journal-title":"J Extra Corpor Technol"},{"key":"10.1016\/j.jtha.2026.03.017_bib56","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1051\/ject\/202052212","article-title":"Can we rely on the activated clotting time to measure heparin anticoagulation? A clinical evaluation of two ACT monitors","volume":"52","author":"Nilsson","year":"2020","journal-title":"J Extra Corpor Technol"},{"key":"10.1016\/j.jtha.2026.03.017_bib57","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/00000542-200307000-00012","article-title":"Evaluation of a new point-of-care celite-activated clotting time analyzer in different clinical settings. The i-STAT celite-activated clotting time test","volume":"99","author":"Paniccia","year":"2003","journal-title":"Anesthesiology"},{"key":"10.1016\/j.jtha.2026.03.017_bib58","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/S0002-9149(99)00582-2","article-title":"Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris","volume":"84","author":"Rabah","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jtha.2026.03.017_bib59","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.thromres.2011.12.025","article-title":"Sustained heparin effect contributes to reduced plasma thrombin generation capacity early after cardiac surgery","volume":"130","author":"Radulovic","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.03.017_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0130271","article-title":"Heparin and protamine titration does not improve haemostasis after cardiac surgery: a prospective randomized study","volume":"10","author":"Radulovic","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jtha.2026.03.017_bib61","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1160\/TH07-04-0307","article-title":"Monitoring high-dose heparinization during cardiopulmonary bypass\u2014a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays","volume":"99","author":"Raivio","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.03.017_bib62","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/bjh.17263","article-title":"The heparin-von Willebrand factor interaction and conventional tests of haemostasis\u2014the challenges in predicting bleeding in cardiopulmonary bypass","volume":"192","author":"Ranger","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2026.03.017_bib63","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1191\/0267659103pf672oa","article-title":"Heparin monitoring during cardiac surgery. Part 1: Validation of whole-blood heparin concentration and activated clotting time","volume":"18","author":"Raymond","year":"2003","journal-title":"Perfusion"},{"key":"10.1016\/j.jtha.2026.03.017_bib64","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1191\/0267659103pf673oa","article-title":"Heparin monitoring during cardiac surgery. Part 2: calculating the overestimation of heparin by the activated clotting time","volume":"18","author":"Raymond","year":"2003","journal-title":"Perfusion"},{"key":"10.1016\/j.jtha.2026.03.017_bib65","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1055\/s-0035-1570035","article-title":"Antifactor Xa activity for the management of anticoagulation during cardiac surgery","volume":"64","author":"Reyher","year":"2016","journal-title":"Thorac Cardiovasc Surgeon"},{"key":"10.1016\/j.jtha.2026.03.017_bib66","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/ajcp\/109.4.371","article-title":"The diagnostic accuracy of bedside and laboratory coagulation: procedures used to monitor the anticoagulation status of patients treated with heparin","volume":"109","author":"Solomon","year":"1998","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jtha.2026.03.017_bib67","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00540-007-0506-1","article-title":"Heparin anticoagulation in patients undergoing off-pump and on-pump coronary bypass surgery","volume":"21","author":"Tanaka","year":"2007","journal-title":"J Anesth"},{"key":"10.1016\/j.jtha.2026.03.017_bib68","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1053\/j.jvca.2014.04.024","article-title":"Protamine requirements in cardiac surgery: effect of changes in the heparin reference standard","volume":"28","author":"Taneja","year":"2014","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.jtha.2026.03.017_bib69","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s12630-009-9098-6","article-title":"Elevated activated partial thromboplastin time does not correlate with heparin rebound following cardiac surgery","volume":"56","author":"Taneja","year":"2009","journal-title":"Can J Anesth"},{"key":"10.1016\/j.jtha.2026.03.017_bib70","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12630-022-02364-4","article-title":"Minimum protamine dose required to neutralize heparin in cardiac surgery: a single-centre, prospective, observational cohort study","volume":"70","author":"Taneja","year":"2023","journal-title":"Can J Anesth"},{"key":"10.1016\/j.jtha.2026.03.017_bib71","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jtcvs.2003.12.023","article-title":"Can extra protamine eliminate heparin rebound following cardiopulmonary bypass surgery?","volume":"128","author":"Teoh","year":"2004","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtha.2026.03.017_bib72","first-page":"Ii420","article-title":"Heparin binding proteins. Contribution to heparin rebound after cardiopulmonary bypass","volume":"88","author":"Teoh","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2026.03.017_bib73","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1051\/ject\/1995274192","article-title":"The effect of hypothermia on heparin anticoagulation as measured by activated clotting time and factor Xa inhibition","volume":"27","author":"Tian","year":"1995","journal-title":"J Extra Corpor Technol"},{"key":"10.1016\/j.jtha.2026.03.017_bib74","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1177\/02676591231160268","article-title":"Clues of incomplete reversal of heparin in cardiac surgery","volume":"39","author":"Tiquet","year":"2024","journal-title":"Perfusion"},{"key":"10.1016\/j.jtha.2026.03.017_bib75","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S1053-0770(05)80002-3","article-title":"A new method of measuring heparin levels in whole blood by protamine titration using a heparin-responsive electrochemical sensor","volume":"10","author":"Wahr","year":"1996","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.jtha.2026.03.017_bib76","doi-asserted-by":"crossref","DOI":"10.1177\/1076029620946843","article-title":"Is there a \u201cblind spot\u201d in point-of-care testing for residual heparin after cardiopulmonary bypass? A prospective, observational cohort study","volume":"26","author":"Wand","year":"2020","journal-title":"Clin Appl Thromb Hemost"},{"issue":"Pt B","key":"10.1016\/j.jtha.2026.03.017_bib77","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.avsg.2024.10.003","article-title":"Ability of activated clotting time measurements to monitor unfractionated heparin activity during noncardiac arterial procedures","volume":"110","author":"Hoebink","year":"2025","journal-title":"Ann Vasc Surg"},{"key":"10.1016\/j.jtha.2026.03.017_bib78","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1055\/s-0038-1650684","article-title":"More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT","volume":"76","author":"Despotis","year":"1996","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.03.017_bib79","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1053\/j.jvca.2022.12.019","article-title":"Heparin rebound: an in-depth review","volume":"37","author":"Stone","year":"2023","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.jtha.2026.03.017_bib80","series-title":"Stago launches ready to use heparin anti-Xa assay","year":"2011"},{"key":"10.1016\/j.jtha.2026.03.017_bib81","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients","volume":"8","author":"Schulman","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.03.017_bib82","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.avsg.2025.07.041","article-title":"Validation of the E-CABG bleeding severity classification in open peripheral arterial surgery","volume":"122","author":"Steunenberg","year":"2026","journal-title":"Ann Vasc Surg"},{"key":"10.1016\/j.jtha.2026.03.017_bib83","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1001\/jama.285.14.1865","article-title":"Predictors of cardiac events after major vascular surgery: role of clinical characteristics, dobutamine echocardiography, and beta-blocker therapy","volume":"285","author":"Boersma","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2026.03.017_bib84","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.1016\/j.thromres.2010.05.028","article-title":"Plasma activity of individual coagulation factors, hemodilution and blood loss after cardiac surgery: a prospective observational study","volume":"126","author":"Ternstr\u00f6m","year":"2010","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.03.017_bib85","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.tmrv.2006.03.003","article-title":"Effects of cardiac surgery on hemostasis","volume":"20","author":"Hartmann","year":"2006","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.jtha.2026.03.017_bib86","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/j.jtha.2025.02.026","article-title":"How to deal with interference on heparin anti-Xa activity caused by oral factor FXa inhibitors: communication from the ISTH SSC Subcommittee on Control of Anticoagulation","volume":"23","author":"Gendron","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.03.017_bib87","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1111\/jth.14969","article-title":"Monitoring unfractionated heparin therapy: Lack of standardization of anti-Xa activity reagents","volume":"18","author":"Smahi","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.03.017_bib88","unstructured":"ECAT Foundation. External quality control for survey: assays and tests with a focus on thrombosis and haemostasis. Voorschoten, Netherlands: ECAT Foundation. SURVEY 2023-A4 Anticoagulation, Labcode 414."},{"key":"10.1016\/j.jtha.2026.03.017_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2022.100031","article-title":"Viscoelastic testing: an illustrated review of technology and clinical applications","volume":"7","author":"Hartmann","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.03.017_bib90","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1111\/jth.15529","article-title":"Thrombin generation assays are versatile tools in blood coagulation analysis: a review of technical features, and applications from research to laboratory routine","volume":"19","author":"Depasse","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.03.017_bib91","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.tracli.2021.03.003","article-title":"Clinical impact of rotational thromboelastometry in cardiac surgery","volume":"28","author":"Herruzo","year":"2021","journal-title":"Transfus Clin Biol"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626002072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626002072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:13:50Z","timestamp":1781525630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783626002072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":91,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1538783626002072"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2026.03.017","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical applicability of anti-Xa measurements to monitor unfractionated heparin activity during arterial procedures: a scoping review","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2026.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}